Abstract. Biliary cancer (BC) is an aggressive neoplasm with high mortality. BC can be categorized into three groups: intrahepatic cholangiocarcinoma (CCA; also known as bile duct cancer), extrahepatic cholangiocarcinoma, and gallbladder cancer. Due to its heterogeneity and aggressiveness, the response to current chemotherapy and radiotherapy methods in patients with BC is poor. Therefore, there is an urgent requirement to develop drugs to treat BC. Piperlongumine (PL), a naturally occurring small molecule isolated from *Piper longum L.*, exhibits anticancer activity by inducing reactive oxygen species (ROS) production. In the present study, the effects of PL on cell proliferation, cell cycle, apoptosis, and autophagy in BC cells were investigated. PL induced BC cell death in a concentration- and time-dependent manner by inducing ROS production. PL induced cell cycle arrest in CCA cells (HuCCT-1) and gallbladder cancer cells (OCUG-1) cells, but with distinct cell cycle distribution profiles. PL caused G2/M cell cycle arrest in HuCCT-1 cells, and G0/G1 cell cycle arrest in OCUG-1 cells. PL induced apoptosis and autophagy; PL treatment induced accumulation of LC3-II in a concentration- and time-dependent manner. The Erk signaling pathway appeared to be involved in autophagy induction. Application of the ROS scavenger, N-acetyl-l-cysteine, to BC cells attenuated the cell death, cell cycle arrest, apoptosis, and autophagy induced by PL treatment. These findings indicated that PL may be a potential agent for BC treatment in the future.

Introduction

Biliary cancer (BC) is an aggressive neoplasm with high mortality. Although the incidence of BC is relatively low, it is increasing (1,2). Based on its anatomic origin, BC can be categorized as intrahepatic or extrahepatic cholangiocarcinoma (CCA), or gallbladder cancer (3). The treatment options for BC include surgery, chemotherapy, and radiation therapy (4). Surgery is the most curative therapy for BC, but most patients present an advanced disease stage at diagnosis and are not suitable for surgical resection (5). Furthermore, numerous patients exhibit recurrent BC even following complete surgical resection (4). Several drugs are now used for adjuvant or systemic chemotherapy in patients with advanced or recurrent BC (6); a regimen based on the combination of gemcitabine and cisplatin is regarded as a first-line treatment for patients with advanced BC. Studies have shown a survival benefit for patients with BC after receiving chemotherapy (7,8). However, owing to its heterogeneity and aggressiveness, the overall 5-year survival rate remains low (9). Therefore, there is an urgent requirement to develop novel therapeutic medicines for BC treatment.

Reactive oxygen species (ROS) are active oxygen-containing molecules that have long been considered as by-products of cellular metabolism (10,11). ROS can be produced by mitochondrial respiration, the NADPH oxidase complex and other biochemical reactions (6,10). Excessive ROS production may be harmful to cells, resulting in oxidative damage to DNA, proteins, and lipids, as well as genetic instability (11). Elevated ROS levels are often observed in cancer cells (12), which may be due to the compromised ROS-scavenging ability of these cells (13). Increased ROS levels can drive abnormal proliferation of cancer cells. Simultaneously, elevated ROS levels increase the sensitivity of these cancer cells to cell death, making them more vulnerable to ROS induction (14). Therefore, a strategy to induce anticancer effects is increasing ROS levels to selectively kill cancer cells without causing damage to normal cells (9,15). Recently, ROS-inducing drugs have been investigated to target various cancer cells, including colon cancer (16), prostate cancer (17), pancreatic cancer (18) and glioblastoma (19) cells. Due to the heterogeneity of BC, drugs targeting the signaling pathways of BC cells are not currently available. Increased ROS production has been...
reported in BC cells (20). Thus, it is important to develop drugs that can induce ROS levels to interfere with the redox balance in BC cells.

Piperlongumine (PL) is a natural product isolated from the long pepper, *Piper longum* L. PL induces high levels of ROS production (21). It possesses selective anticancer activity in colon, ovarian, prostate, breast, pancreatic, head and neck, and renal cancers via multiple signaling pathways, including the p38/JNK, MAPK-C/EBP homologous protein and NF-κB signaling pathways (20,22-24), causing apoptosis or autophagy in cancer cells. However, whether PL can induce autophagy in BC cells is yet to be determined. In this study, the cytotoxic effects of PL in BC cells were investigated. In addition, autophagy in PL-treated cells was assessed, and the underlying signaling pathways induced by PL treatment were explored.

**Materials and methods**

**Cell lines and cell culture.** The human biliary epithelial tumor cell line HuCCT-1 and the gallbladder carcinoma cell line OCUG-1 were obtained from the Japanese Collection of Research Bioresources Cell Bank. HuCCT-1 and OCUG-1 cells were cultured in RPMI 1640 medium (Gibco; Thermo Fisher Scientific, Inc.) and Dulbecco’s Modified Eagle’s medium (Gibco; Thermo Fisher Scientific, Inc.), respectively, both containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), and antibiotic and antimycotic solution (penicillin, 10 U/ml; streptomycin sulfate, 10 µg/ml; amphotericin B, 25 ng/ml). These cell lines were tested for the absence of mycoplasma contamination. The cells were incubated in a humidified atmosphere containing 5% CO₂ at 37°C.

**Reagents and antibodies.** PL was purchased from Cayman Chemical Company. Proteins were extracted with M-PER mammalian protein extraction reagent buffer (Thermo Fisher Scientific, Inc.) for western blotting. Protease inhibitor was purchased from EMD Millipore. Primary antibodies for caspase 3 (polyclonal, rabbit anti-human; 1:1,500; cat. no. 9662S), PARP (monoclonal, rabbit anti-human; 1:1,000; cat. no. 9532S), cdc25C (monoclonal, rabbit anti-human; 1:1,000; cat. no. 4688S), cyclin D1 (monoclonal, mouse anti-human; 1:2,000; cat. no. 2947S), cyclin-dependent kinase (CDK)2 (monoclonal, rabbit anti-human; 1:1,000; cat. no. 2546S), phosphorylated (p)-Erk1/2 [monoclonal, rabbit anti-human (Thr202/Tyr204); 1:1,000; cat. no. 4370S], and Erk1/2 (monoclonal, rabbit anti-human; 1:1,000; cat. no. 4695S) were all purchased from Abgent, Inc. β-actin or GAPDH expression was used as an internal control for western blotting. The antibody against β-actin (monoclonal, mouse anti-human; 1:7,500; cat. no. sc-47778) was purchased from Santa Cruz Biotechnology, Inc. The antibody against GAPDH (monoclonal, rabbit anti-human; 1:1,000; cat. no. 2118S) was purchased from Cell Signaling Technology, Inc. N-acetyl-L-cysteine (NAC) and 2′,7′-dichlorodihydrofluorescein diacetate (H₂DCFDA) were purchased from Sigma-Aldrich (Merck KGaA). PD98059 (cat. no. 9900; Cell Signaling Technology, Inc.), an inhibitor of mitogen-activated protein kinase (MAPK) kinase (MEK1) activation and the MAPK cascade, was used in the experiment. For experiments involving this inhibitor, HuCCT-1 cells were pretreated in the presence or absence of PD98059 (20 or 30 µM) at 37°C for 1 h in a humidified incubator, followed by PL treatment (5 or 7.5 µM for western blotting; 10 or 20 µM for ROS analysis) for 24 h. Cells were then harvested for analyses.

**ROS analysis.** To determine the ROS level in BC cells, 1x10⁶ cells were seeded in 6-well plates. The cells were pretreated with NAC (3 mM) or DMSO in a humidified incubator at 37°C for 1 h. Then, the cells were treated with 10 µM CM-H₂DCFDA, incubated at 37°C in the dark for 30 min. Cells were treated with various concentrations of PL (10 or 20 µM for HuCCT-1 cells; 30 or 60 µM for OCUG-1 cells) in a humidified incubator at 37°C for 1 h. After washing the cells, cells were trypsinized and the ROS level was determined by using flow cytometry (FACSCanto II; BD Biosciences) and analyzed by BD FACS Diva software (v6.1.3; BD Biosciences).

**Cell viability analysis and colony formation assay.** Cell viability was determined by using a Cell Counting Kit-8 (CCK-8) proliferation assay (Sigma-Aldrich; Merck KGaA) according to the manufacturer’s protocols. The absorbance values were read at 490 nm at 2 h following the addition of CCK-8 reagent. Briefly, 1x10⁶ HuCCT-1 cells were seeded in 96-well plates, pretreated with NAC as aforementioned and then treated with 2.5, 5 or 10 µM PL, and incubated for 24 and 48 h at 37°C in a humidified incubator, at which point 100 µL CCK-8 reagent (mixed 1:20 in medium) was added to each well. The values of vehicle-treated cells were used for normalization. Three independent experiments were conducted. The assay protocol for OCUG-1 cells was the same, except for the concentration of PL (5, 10 or 20 µM). For the colony formation assay, 1x10³ cells were seeded in 6-well plates. At day 7 after cell plating, the cells were washed and fixed with 10% formaldehyde at 25°C for 10 min, and stained with 0.05% crystal violet (Sigma-Aldrich; Merck KGaA) at 25°C for 15 min. The colonies were scanned and analyzed with ImageJ software (FIji-win32; National Institutes of Health).

**Cell cycle analysis.** For determination of cell cycle profile, 1x10⁵ cells were seeded in 6-well plates. After serum starvation for 24 h, the cells were treated with PL (5 or 10 µM for HuCCT-1 cells; 15 or 30 µM for OCUG-1 cells) and/or NAC as aforementioned and harvested at 24 and 48 h. The cells were then fixed by using 100% methanol for 24 h at 4°C. Propidium iodide (PI; 0.05 mg/ml) solution containing RNase was added to the methanol-fixed cells. The cells were then incubated at 25°C in the dark for 30 min. The DNA content was analyzed
by performing flow cytometry to determine the percentage of cells in each phase of the cell cycle using ModFit LT 3.3 cell cycle analysis software (Verity Software House).

Detection of apoptosis by flow cytometric analysis. The percentage of apoptotic cells was determined after PL treatment. The cells were treated with PL for 24 and 48 h, harvested and subjected to Annexin V and PI staining (5 µl Annexin V-FITC and 5 µl PI in 500 µl binding buffer) at 25°C for 5 min in the dark using an apoptosis detection kit (BioVision, Inc.). Apoptotic cells were determined using flow cytometry (FACSCanto II; BD Biosciences) and analyzed using BD FACSDiva software (v6.1.3). The apoptotic ratio was calculated based on the percentage early + late apoptotic cells.

Cell lysate preparation and western blotting. Cells were lysed and extracted by using M-PER mammalian protein extraction reagent (Thermo Fisher Scientific, Inc.) containing protease inhibitor cocktail (Cell Signaling Technology, Inc.). Bio-Rad Protein Assay reagent (Bio-Rad Laboratories, Inc.) was used to determine the concentration of extracted protein. Protein (40 µg/lane) was subjected to 12.5% SDS-PAGE and electrotransferred onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories, Inc.). The membrane was blocked by incubation with 5% skim milk (Sigma-Aldrich; Merck KGaA) at 25°C for 1 h, followed by probing with specific primary antibodies at 4°C for 16 h. The membrane was then incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:5,000; cat. no. 111-035-003) or goat anti-mouse IgG (1:5,000; cat. no. 115-035-003) secondary antibodies (Jackson ImmunoResearch Laboratories, Inc.) for 2 h at 25°C. Protein expression was detected using an enhanced chemiluminescence horseradish peroxidase substrate detection kit (cat. no. WBKLS0500; EMD Millipore) and quantified using a UVP BioSpectrum 800 Imaging System (UVP, LLC).

Immunofluorescence assay. HuCCT-1 cells cultured on coverslips were fixed with ice-cold acetone and methanol (2:1) at -20°C for 30 min and then blocked with 5% normal horse serum (Gibco; Thermo Fisher Scientific, Inc.) in phosphate-buffered saline (PBS) for 30 min at 25°C. The cells were then washed with PBS and incubated for 1 h at 4°C with LC-3 antibody (1:100 in 5% normal horse serum). After washing with PBS, the cells were incubated with goat anti-rabbit IgG secondary antibody conjugated with Alexa Fluor® 488 (1:7,500; cat. no. A-11008; Invitrogen; Thermo Fisher Scientific, Inc.) for 1 h at 25°C. Next, the cells were washed again with PBS and stained with 1 µg/ml DAPI in PBS at 25°C for 5 min. The coverslips were mounted with anti-fading solution (Sigma-Aldrich; Merck KGaA) and examined under fluorescence microscopy (magnification, 200; Olympus 1X81; Olympus Corporation).

Statistical analysis. Statistical significance was determined using the GraphPad Prism 5.0 software (GraphPad Software, Inc.). The data were analyzed using two-way analysis of variance followed by Bonferroni post hoc test for multiple comparisons. All in vitro experiments were repeated three times and the results are presented as means ± SD. P<0.05 was considered to indicate a statistically significant difference.

Results

PL exhibits growth inhibitory activity against BC cells, which is attenuated by a ROS inhibitor. To determine the inhibitory effects of PL on BC cell proliferation, HuCCT-1 and OCUG-1 cells were treated with different concentrations of PL for 24 and 48 h. Cell survival rates were analyzed using a CCK-8 assay. PL treatment produced a significant cytotoxic effect on both HuCCT-1 (Fig. 1A) and OCUG-1 (Fig. 1B) cells. HuCCT-1 exhibited greater sensitivity to PL treatment, with IC50 values of 24.8 and 4.2 µM at 24 and 48 h, respectively. The IC50 of PL for OCUG-1 cells at 24 and 48 h was 22.2 and 13.8 µM, respectively. Cell proliferation was then evaluated using a clonogenic assay. As shown in Fig. 1C and D, PL treatment decreased the colony number in a concentration-dependent manner, and HuCCT-1 cells exhibited a more pronounced response to PL treatment than OCUG-1 cells.

It was then determined whether the cytotoxicity of PL to HuCCT-1 and OCUG-1 cells was due to an imbalance in redox status. ROS levels were measured via flow cytometric analysis in PL-treated cells in the presence or absence of the ROS scavenger NAC. The data from cytometric analysis demonstrated that PL treatment increased ROS levels in a concentration-dependent manner (Fig. S1). Furthermore, the reduction in ROS levels was associated with the rescue of cell death in NAC-treated cells (Fig. 1). The reversal of cell death by NAC showed a significant difference, most notably in high-concentration PL-treated cells and those treated with PL for a long duration. Collectively, these data suggested that PL exhibits substantial cytotoxicity by interfering with the redox balance in HuCCT-1 and OCUG-1 cells.

PL interferes with cell cycle progression in HuCCT-1 and OCUG-1 cells. To determine the mechanism underlying the antiproliferative effects of PL, the cell cycle distribution profiles of HuCCT-1 and OCUG-1 cells following PL treatment were determined via flow cytometric analysis. As shown in Fig. 2A, HuCCT-1 cells showed G2/M phase arrest after PL treatment. The G2/M cell distribution was increased from 20.8±2.8 and 14.3±1.1% in the vehicle control group to 45.4±6.8 and 30.3±7.0% in 5 µM PL-treated HuCCT-1 cells after treatment for 24 and 48 h, respectively. In contrast, OCUG-1 cells exhibited G0/G1 phase arrest after PL treatment (Fig. 2B). The G0/G1 cell distribution increased from 46.8±1.5 and 63.3±0.4% in the vehicle control group to 87.5±0.62 and 75.1±1.5% in 15 µM PL-treated OCUG-1 cells after treatment for 24 and 48 h, respectively. Similar cell cycle arrest was observed in 10 and 30 µM PL-treated HuCCT-1 and OCUG-1 cells. Pretreatment with NAC partially reversed the cell cycle arrest induced by PL in both HuCCT-1 and OCUG-1 cells. Additionally, an increase in the sub-G1 cell population was observed in 10 and 30 µM PL-treated HuCCT-1 and OCUG-1 cells.

To further verify the induction of cell cycle arrest by PL, the expression of cell cycle-associated checkpoint proteins was analyzed via western blotting. Cdc25C is a key protein in...
regulating cell cycle entry into mitosis (25). Cyclin B1-cdc2 complex activation controls cell cycle mitotic progression (26). Cyclin A2 is involved in G2/M transition (22). As shown in Fig. 3A, treatment with PL reduced the protein levels of cdc25C, cyclin B1, cdc2 and cyclin A2 in HuCCT-1 cells. Similarly, the decrease in the expression of these G2/M-regulating proteins induced by PL was attenuated by NAC pretreatment (Fig. 3A).

The proteins p21 and p27 are cyclin-dependent kinase inhibitors that bind to and inhibit the activity of CDK2, CDK1 and CDK4/6 complexes; both p21 and p27 are thus regarded as regulators of cell cycle progression to G1 phase (27). The results of western blotting showed that PL treatment increased the expression of these G2/M-regulating proteins induced by PL was attenuated by NAC pretreatment (Fig. 3A).

PL induces apoptosis and autophagy in HuCCT-1 and OCUG-1 cells. Whether PL can induce apoptotic cell death in BC cells was further analyzed. HuCCT-1 and OCUG-1 cells were treated with different concentrations of PL for 48 h. Apoptotic cells were determined via flow cytometry using Annexin V/PI double staining. As presented in Fig. 4A and B, PL treatment resulted in increased Annexin-V staining in a concentration-dependent manner, which indicates apoptotic cell death. The apoptotic ratio in HuCCT-1 cells was 10.6±3.3% at 5 µM and 26.0±4.9% at 10 µM PL vs. 4.7±1.4% in the vehicle control cells. The apoptotic ratio in OCUG-1 cells was 30.9±6.3% at 15 µM and 55.1±4.5% at 30 µM PL vs. 28.3±3.4% in the vehicle control cells. When the cells were pretreated with NAC, the apoptotic ratio decreased from 30.9±6.3% to 12.5±3.1% and 55.1±4.5 to 35.2±2.3% in HuCCT-1 and OCUG-1 cells, respectively. Western blotting was then performed to determine whether caspases were involved in PL-induced apoptosis. However, only a faint increase in caspase 3 cleavage was observed in HuCCT-1 cells (Fig. 5A), with no clear increase in OCUG-1 cells after PL treatment, as determined via western blot analysis (Fig. 5B). Similar to the results of caspase 3 cleavage, no clear increase in PARP cleavage was detected after PL treatment (Fig. 5A and B).

During autophagy, cytoplasmic LC3-I is conjugated to phosphatidyl ethanolamine to form LC3-II (28). As shown in Fig. 5A and B, LC3-II expression increased after PL treatment in HuCCT-1 and OCUG-1 cells. A reduction in LC3-II expression was observed when the cells were pretreated with NAC prior to PL application.

PL induces apoptosis and autophagy in HuCCT-1 and OCUG-1 cells. Whether PL can induce autophagy was further analyzed. HuCCT-1 and OCUG-1 cells were treated with different concentrations of PL for 48 h. Apoptotic cells were determined via flow cytometry using Annexin V/PI double staining. As presented in Fig. 4A and B, PL treatment resulted in increased Annexin-V staining in a concentration-dependent manner, which indicates autophagic cell death. The autophagic ratio in HuCCT-1 cells was 10.6±3.3% at 5 µM and 26.0±4.9% at 10 µM PL vs. 4.7±1.4% in the vehicle control cells. The autophagic ratio in OCUG-1 cells was 30.9±6.3% at 15 µM and 55.1±4.5% at 30 µM PL vs. 28.3±3.4% in the vehicle control cells. When the cells were pretreated with NAC, the autophagic ratio decreased from 30.9±6.3% to 12.5±3.1% and 55.1±4.5 to 35.2±2.3% in HuCCT-1 and OCUG-1 cells, respectively. Western blotting was then performed to determine whether caspases were involved in PL-induced apoptosis. However, only a faint increase in caspase 3 cleavage was observed in HuCCT-1 cells (Fig. 5A), with no clear increase in OCUG-1 cells after PL treatment, as determined via western blot analysis (Fig. 5B). Similar to the results of caspase 3 cleavage, no clear increase in PARP cleavage was detected after PL treatment (Fig. 5A and B).

During autophagy, cytoplasmic LC3-I is conjugated to phosphatidyl ethanolamine to form LC3-II (28). As shown in Fig. 5A and B, LC3-II expression increased after PL treatment in HuCCT-1 and OCUG-1 cells. A reduction in LC3-II expression was observed when the cells were pretreated with NAC prior to PL application.
Figure 2. PL induces cell cycle arrest in biliary cancer cells. (A) HuCCT-1 and (B) OCUG-1 cells were treated with the indicated concentrations of PL for 24 or 48 h with or without NAC pretreatment. Cell cycle distribution was analyzed by flow cytometry. The Sub-G1 cell population was determined after flow cytometric analysis. PL concentrations are in µM. Data are presented as the mean ± SD of at least three independent experiments. *P<0.05. PL, piperlongumine; NAC, N-acetyl-l-cysteine.
Figure 3. PL induces altered expression of cell cycle-associated proteins in biliary cancer cells. (A) HuCCT-1 and (B) OCUG-1 cells were treated with the indicated concentrations of PL for 24 or 48 h with or without NAC pretreatment. CDK, cyclin-dependent kinase; PL, piperlongumine; NAC, N-acetyl-l-cysteine.

Figure 4. PL induces apoptosis in HuCCT-1 and OCUG-1 cells. (A) HuCCT-1 and (B) OCUG-1 cells were treated with the indicated concentrations of PL for 48 h with or without NAC pretreatment. Apoptotic cells were determined by PI and Annexin-V staining, and analyzed via flow cytometry. Data are presented as the mean ± SD of at least three independent experiments. "P<0.01, ""P<0.001. PL, piperlongumine; NAC, N-acetyl-l-cysteine.
be detected using immunofluorescence staining. LC-3 puncta were analyzed in PL-treated cells using an LC3-specific antibody. As shown in Fig. 6C, a clear increase in LC-3 puncta was detected after PL treatment, and a decrease with Erk inhibition in pretreated HuCCT-1 cells. These data suggested that PL treatment induces autophagy via ROS-mediated Erk signaling. To further determine whether ROS accumulation was upstream of Erk activation in PL-treated HuCCT-1 cells, an MEK inhibitor, PD98059, was used to analyze ROS levels in PL-treated HuCCT-1 cells. The results of flow cytometry showed that pretreatment with the MEK inhibitor did not affect ROS levels in PL-treated cells (Fig. S2). Then, HuCCT-1 cells were pretreated with PD98059 followed by PL treatment, and apoptosis was analyzed using flow cytometry. The apoptotic cell ratio increased from 13.2±3.2% in PL-treated cells to 16.5±3.0% in cells pretreated with PD98059 followed by PL application (Fig. 7A). It was hypothesized that if autophagy was blocked by Erk inhibition in PL-treated HuCCT-1 cells, the cells would undergo apoptosis. However, there was no significant difference in the apoptotic rate of HuCCT-1 cells with or without pretreatment with PD98059 (Fig. 7A). The expression of apoptosis-associated proteins was detected by western blotting. PD98059 decreased the LC3-II level in PL-treated HuCCT-1 cells, but increased the cleaved forms of caspase 3 and PARP (Fig. 7B). The relative level of LC3-II for each treatment was quantified using a UVP image system. A significant reduction in LC3-II was observed following pre-treatment with a high concentration of PD98059 (30 µM) before application of 7.5 µM PL to HuCCT-1 cells (Fig. 7C).

**Discussion**

BC represents a heterogeneous malignancy with poor prognosis. Therefore, there is an urgent requirement to develop new drugs for BC treatment. The aim of the present study was to determine the inhibitory effects of PL on BC cell growth. It was found that PL exhibited cytotoxicity in HuCCT-1 and OCUG-1 cells by interfering with redox balance via ROS production. It was also determined that PL induced cell cycle arrest, apoptosis and autophagy via ROS-activated Erk signaling in HuCCT-1
Figure 7. Inhibition of the Erk signaling pathway increases apoptosis in PL-treated HuCCT-1 cells. (A) HuCCT-1 cells were pretreated in the presence or absence of the MEK inhibitor PD98059 (20 µM) followed by treated with 10 µM PL for 24 h. Apoptotic cells were analyzed by flow cytometry. The x- and y-axes represent the fluorescence intensity of Annexin V-FITC and PI fluorescence in HuCCT-1 cells, respectively. (B) HuCCT-1 cells were treated with 5 or 7.5 µM PL in the presence or absence of various concentrations of the MEK inhibitor PD98059 for 24 h. Expression levels of Erk, PARP, LC3 and caspase 3 proteins were analyzed via western blotting. (C) Quantification of LC3-II expression relative to the DMSO control group is presented. Data are presented as the mean ± SD of at least three independent experiments. *P<0.05, **P<0.01, ***P<0.001; n.s., not significant. LC3, microtubule-associated protein 1A/1B light chain 3B; MEK, mitogen-activated protein kinase kinase; p, phosphorylated; PARP, poly(ADP-ribose) polymerase; PI, propidium iodide; PL, piperlongumine.
cells, and transiently in OCUG-1 cells. The present findings indicated that PL is a potential drug for BC treatment. Cancer cells are more vulnerable to ROS-mediated effects owing to elevated ROS levels (15). PL inhibits the antioxidant enzyme glutathione S-transferase P, leading to elevated ROS production and subsequently resulting in cancer cell death (29,30). In the present study, it was revealed that PL treatment at lower doses induced ROS production in HuCCT-1 cells, indicating that HuCCT-1 cells were sensitive to PL treatment. The IC₅₀ calculated using a CCK-8 assay supported this hypothesis. HuCCT-1 cells exhibited more sensitive responses than OCUG-1 cells to PL treatment, with IC₅₀ values of 4.2 and 13.8 µM at 48 h, respectively. Recently, PL has been shown to exhibit cytotoxicity in other CCA cells (KKU-055, KKU-100, KKU-139, KKU-213 and KKU-214) (31). PL showed similar IC₅₀ values in these cells, ranging between 4 and 20 µM, suggesting that PL is a potent anticancer drug for treating CCA.

High ROS levels in cells result in cell cycle arrest and subsequent cell death (32). It was demonstrated that PL interfered with cell cycle progression in both HuCCT-1 and OCUG-1 cells. It is proposed that PL may induce G2/M cell cycle arrest in HuCCT-1 cells. Phosphorylation and dephosphorylation of cdc2 at tyrosine 15 by Wee1 and cdc25, respectively, cooperatively control the cdc2/cyclin B complex and regulate cell cycle entry into mitosis (33). Therefore, phosphorylation of cdc2 at tyrosine 15 is an effective marker of G2/M cycle arrest; however, only the protein expression levels of cdc25C, cyclin B1, cdc2 and cyclin A2 were analyzed in this study.

The expression levels of antioxidant genes may determine differential responses after PL treatment (31). Thongsom et al (31) determined the mRNA expression levels of five antioxidant genes, including PARK1, TXN, NQO1, HO-1 and SOD2, in CCA cells. Among the proteins encoded by these genes, heme oxygenase-1 (HO-1) expression may be a major factor contributing to the antioxidant capacity of CCA cells. Consistent with this finding, HO-1 expression contributed to the differential responses of breast cancer cells to PL treatment (34). HO-1 expression is also inversely associated with survival in patients with CCA (35). The higher antioxidant capacity of OCUG-1 cells may be due to upregulated expression of antioxidant genes compared with HuCCT-1 cells; however, this requires further investigation.

PL was reported to induce apoptosis in CCA cell lines (KKU-055, KKU-100, KKU-139, KKU-213 and KKU-214) (31). PL inhibits the antioxidant enzyme glutathione S-transferase P, leading to elevated ROS production and subsequently resulting in cancer cell death (29,30). In the present study, it was revealed that PL induced autophagy in CCA cells, and transiently in OCUG-1 cells. The present findings indicated that PL is a potential drug for BC treatment. Cancer cells are more vulnerable to ROS-mediated effects owing to elevated ROS levels (15). PL inhibits the antioxidant enzyme glutathione S-transferase P, leading to elevated ROS production and subsequently resulting in cancer cell death (29,30). In the present study, it was revealed that PL treatment at lower doses induced ROS production in HuCCT-1 cells, indicating that HuCCT-1 cells were sensitive to PL treatment. The IC₅₀ calculated using a CCK-8 assay supported this hypothesis. HuCCT-1 cells exhibited more sensitive responses than OCUG-1 cells to PL treatment, with IC₅₀ values of 4.2 and 13.8 µM at 48 h, respectively. Recently, PL has been shown to exhibit cytotoxicity in other CCA cells (KKU-055, KKU-100, KKU-139, KKU-213 and KKU-214) (31). PL showed similar IC₅₀ values in these cells, ranging between 4 and 20 µM, suggesting that PL is a potent anticancer drug for treating CCA.

High ROS levels in cells result in cell cycle arrest and subsequent cell death (32). It was demonstrated that PL interfered with cell cycle progression in both HuCCT-1 and OCUG-1 cells. It is proposed that PL may induce G2/M cell cycle arrest in HuCCT-1 cells. Phosphorylation and dephosphorylation of cdc2 at tyrosine 15 by Wee1 and cdc25, respectively, cooperatively control the cdc2/cyclin B complex and regulate cell cycle entry into mitosis (33). Therefore, phosphorylation of cdc2 at tyrosine 15 is an effective marker of G2/M cycle arrest; however, only the protein expression levels of cdc25C, cyclin B1, cdc2 and cyclin A2 were analyzed in this study.

The expression levels of antioxidant genes may determine differential responses after PL treatment (31). Thongsom et al (31) determined the mRNA expression levels of five antioxidant genes, including PARK1, TXN, NQO1, HO-1 and SOD2, in CCA cells. Among the proteins encoded by these genes, heme oxygenase-1 (HO-1) expression may be a major factor contributing to the antioxidant capacity of CCA cells. Consistent with this finding, HO-1 expression contributed to the differential responses of breast cancer cells to PL treatment (34). HO-1 expression is also inversely associated with survival in patients with CCA (35). The higher antioxidant capacity of OCUG-1 cells may be due to upregulated expression of antioxidant genes compared with HuCCT-1 cells; however, this requires further investigation.

PL was reported to induce apoptosis in CCA cell lines (KKU-055, KKU-100, KKU-139, KKU-213 and KKU-214) (31). In the present study, it was found that PL also induced autophagy in HuCCT-1 and OCUG-1 cells, as indicated by an increase in LC3-II expression and puncta levels compared with HuCCT-1 cells; however, this requires further investigation. Numerous signaling pathways can be involved in autophagy induction. Previously, it was reported that PL exhibits antitumor activity by affecting PI3K/AKT, p38/JNK, MEK/Erk and NF-κB signaling pathways in cancer cells (24,38-40). In the present study, only the Erk pathway was analyzed; it was revealed that the Erk pathway was involved in the anticancer activity of PL in HuCCT-1 cells. Upon inhibition of the Erk signaling pathway, LC3-II expression and puncta levels decreased. Apoptosis was promoted after inhibition of Erk signaling in HuCCT-1 cells. Various molecules have been reported to be involved in the crosstalk between autophagy and apoptosis (41). In the present study, it was not determined as to whether an interaction between autophagy and apoptosis played a role in the effects of PL. Further studies are required to examine the relationship between autophagy and apoptosis following PL treatment in HuCCT-1 cells.

BCs can be divided into intrahepatic and extrahepatic CCA, and gallbladder cancers (3). HuCCT-1 cells were established from malignant cells originating from the intrahepatic bile duct tree, whereas OCUG-1 cells were derived from metastatic peritoneal effusion of gallbladder carcinoma. In the present study, HuCCT-1 and OCUG-1 cells were used to evaluate the cytotoxic effects of PL on BCs. The response of OCUG-1 cells after PL treatment varied from that of HuCCT-1 cells in terms of cell cycle distribution and signaling pathway activation; this may result from their different origins.

In conclusion, it was demonstrated that PL exhibits anticancer activity in HuCCT-1 and OCUG-1 cells. PL treatment interfered with redox balance, and induced apoptosis and autophagy. This is the first report, to our knowledge, showing that PL induced autophagy in BC cells. It was further demonstrated that the Erk signaling pathway was involved in PL-induced autophagy in HuCCT-1 cells. However, this is a preliminary report of the treatment of BC with PL. Further studies, including in vivo animal experiments, should be conducted to determine the efficacy of PL as a treatment of BC.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Ditmanson Medical Foundation Chiayi Christian Hospital (grant no. R107-008).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

SYC designed the research and collected the data. HYH performed the experiments. HPL performed experiments and helped with the literature search. CYF designed the study and drafted the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.
Competing interests

The authors declare that they have no competing interests.

References


